IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1).

Product information

CAS Number: 2055741-39-2

Molecular Weight: 457.62

Formula: C23H32FN5O2Si

Chemical Name: N-(5-fluoro-2-methylphenyl)-6, 6-dimethyl-3-[1-(trimethylsilyl)cyclobutaneamido]-1H, 4H, 5H, 6H-pyrrolo[3, 4-c]pyrazole-5-carboxamide

Smiles: CC1(C)C2NN=C(NC(=O)C3(CCC3)[Si](C)(C)C)C=2CN1C(=O)NC1=CC(F)=CC=C1C

InChiKey: FYIUNJAFLWNBAI-UHFFFAOYSA-N

InChi: InChI=1S/C23H32FN5O2Si/c1-14-8-9-15(24)12-17(14)25-21(31)29-13-16-18(22(29,2)3)27-28-19(16)26-20(30)23(10-7-11-23)32(4,5)6/h8-9,12H,7,10-11,13H2,1-6H3,(H,25,31)(H2,26,27,28,30)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

IV-361 has less inhibition on CDK2 (Ki≥1000 nM) or PLK1 (Ki≥5000 nM). IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC50≤100 nM) in periphery blood mononuclear cell (PBMC). IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI50≤100 nM).

In Vivo:

IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116.

Products are for research use only. Not for human use.